Comparative overview of safety of the biologics in rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue SUPPL. 82, 2009, Pages 25-32

  Khraishi, Majed ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Nexus Clinical Research Inc   (Canada)

Author keywords

Anti tumor necrosis factor agents; Biologic therapies; Infection; Malignancy; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALANINE AMINOTRANSFERASE; ATLIZUMAB; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ANXIETY; ASTHENIA; BRONCHOSPASM; CANADA; CARDIOVASCULAR DISEASE; CHILL; CONGESTIVE HEART FAILURE; COUGHING; DEMYELINATING DISEASE; DIARRHEA; DIZZINESS; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIPID BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; LUPUS LIKE SYNDROME; LYMPHOMA; MELANOMA; MUSCLE SPASM; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; THROAT IRRITATION; TREATMENT CONTRAINDICATION; TUBERCULOSIS; URINARY TRACT INFECTION; URTICARIA; DRUG ANTAGONISM; IMMUNOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOCONJUGATES; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449136094     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090128     Document Type: Review

References (62)

1. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor-α(TNF-α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005;64 Suppl 4:iv2-14.
2. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-3022
3. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302. (Pubitemid 41368482)
4. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572
5. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005;41 Suppl 3:S189-93. (Pubitemid 41022089)
6. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-4627 (Pubitemid 34441368)
7. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-740 (Pubitemid 19082507)
8. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001;299:119-129 (Pubitemid 34053400)
9. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-426 (Pubitemid 34429950)
10. Long R, GardamMA. Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-1156
11. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-α controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001;166:6728-6734 (Pubitemid 32467216)
12. Rothe J, Lesslauer W, Lötscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802. (Pubitemid 23261759)
13. Deepe GS Jr. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 2005;41 Suppl 3:S204-7.
14. O'Brien DP, Briles DE, Szalai AJ, Tu AH, Sanz I, Nahm MH. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 1999;67:595-601. (Pubitemid 29059192)
15. Moore TA, Lau HY, Cogen AL, Standiford TJ. Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Clin Infect Dis 2005;41 Suppl 3:S213-7. (Pubitemid 41022094)
16. Ndejembi M, Patke D, Bingaman A. CTLA-4Ig inhibits IL-2 production and in vivo expansion of antigen-stimulated memory CD4 T cells. Clin Immunol 2005;115:S219-20.
17. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007;9:R38. (Pubitemid 46696552)
18. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285 (Pubitemid 43736578)
19. Saag KG, Teng GG, Patkar NM, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
20. Kievit W, Creemers MC, Fransen J, et al. A higher rate of serious infections in patients treated with TNF alpha blocking agents [abstract]. Arthritis Rheum 2006;54 Suppl:S365.
21. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum2006;54:2368-2376
22. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders 2008;9:52-78. (Pubitemid 351678129)
23. St. Clair EW, Pisetsky DS, Haynes BF. Rheumatoid arthritis. Philadelphia: Lippincott Williams & Wilkins; 2004.
24. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311 (Pubitemid 23068804)
25. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-1757 (Pubitemid 26306889)
26. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-696
27. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-181 (Pubitemid 28325543)
28. Matteson EL, Hickey AR, Maguire L, Tilson H, Urowitz MB. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809-814
29. Wolfe F, Michaud K. The association of new cases of cancer with biologic therapy [abstract]. Arthritis Rheum 2006;Suppl 54:S549.
30. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-894
31. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-2293
32. Singh G, Ramey D, Rausch P, Schettler JD. Serious infections in rheumatoid arthritis: relationship to immunosuppressive use [abstract]. Arthritis Rheum 1999;Suppl 42:S242.
33. FDA briefing document. Update on the TNF blocking agents. FDA 3-4-2003. [Internet. Accessed February 12, 2009.] Available from: http://www.fda.gov/ ohrms/dockets/ac/03/briefing/3930B1-01-B-TNF.Briefing.htm.
34. Lebwohl M, Gottlieb A, Wallis W, Wallis W, Zitnik R. Global safety and efficacy of more than 5 years of etanercept therapy in rheumatoid arthritis [abstract]. American Academy of Dermatology Annual Scientific Meeting; New Orleans, LA; 18-22 February, 2004:P550.
35. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-167 (Pubitemid 44691882)
36. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191-1199
37. Gomez-Reino JJ,Carmona L; BIOBADASERGroup. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.ArthritisRes Ther 2006;8:R29.
38. Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006;65:257-260 (Pubitemid 43132005)
39. Cohen SB, Emery P, Greenwald MW, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
40. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-2359 (Pubitemid 39603081)
41. Bombardieri S, McKenna F, Drosos A, et al. Efficacy and safety of adalimumab (Humira®) in 899 patients with rheumatoid arthritis (RA) who previously failed etanercept and/or infliximab in clinical practice [abstract]. European League Against Rheumatism 2006; Amsterdam, The Netherlands; 21-24 June, 2006:THU0205.
42. Smolen J, Kay J, Doyle MK, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo-controlled GO-AFTER trial [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:OP0010.
43. FDA Briefing Document. Abatacept (CTLA4-Ig) for the treatment of rheumatoid arthritis: product attributes and mechanism of action. [Internet. Accessed February 12, 2009.] Available from: http://www.fda.gov/ohrms/dockets/ ac/05/slides/2005-4170-Slide-Index.htm
44. Thorne C. The efficacy and safety of existing and emerging RA therapies: an evidence based profile. J Rheumatol 2006; 61st Annual Meeting of the Canadian Rheumatology Association; Cancun, Mexico; 17-21 February, 2006.
45. Kremer J, Westhovens R, Moreland L, et al. Efficacy and safety of the selective co-stimulation modulator abatacept with MTX for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in Inadequate responders to Methotrexate) trial [abstract L2]. Arthritis Rheum 2004; Suppl 50: 517.
46. Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
47. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-2816 (Pubitemid 44497759)
48. Kremer JM, DougadosM, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271 (Pubitemid 41117408)
49. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228-234 (Pubitemid 46226059)
50. Moreland L, Kaine J, Espinoza L, et al. Safety of abatacept in rheumatoid arthritis patients in five double-blind, placebo-controlled trials [abstract]. Arthritis Rheum 2005;52 Suppl:S350.
51. Orencia product monograph. Montreal: Bristol Myers Squibb Canada; June 2006.
52. Smitten A, Covucci A, Simon T. Descriptive analysis of serious infections, hospitalized infections and malignancies over time in the abatacept clinical development program: a safety update with 10,000 person-years of exposure. Ann Rheum Dis 2008;67 Suppl II:338.
53. Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development program: An epidemiological assessment. Ann Rheum Dis 2008 Dec 3. [Epub ahead of print]
54. BMS. Data on file: Overall safety of abatacept: Integrated safety overview; 2007.
55. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
56. Edwards JCW, Szczepanski L, Filipowicz-Sosnowska A, Close D, Stevens RM, Shaw TM. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46 Suppl:S197.
57. Rituxan® product monograph. Mississauga: Hoffmann-La Roche Ltd.; March 2000.
58. Genovese M, Breedveld F, Emery P, et al. Safety of other biologic therapies following rituximab treatment in RA patients [abstract]. Arthritis Rheum 2008;58 Suppl:S785.
59. Nishimoto N, Hashimoto J, Miyasaka N, et al. Blocking interleukin-6 (IL-6) by tocilizumab (a humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA): evidence from a x-ray reader-blinded randomised controlled trial [abstract L27]. Arthritis Rheum 2005; Suppl 52: 71.
60. Maini R, Taylor PC, Pavelka K, et al. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA) [abstract]. Arthritis Rheum 2003;48 Suppl:S652.
61. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-1769 (Pubitemid 38725087)
62. Emery P, Keystone E, Tony HP, et al. Tocilizumab (TCZ) rapidly and significantly improves outcomes in patients with rheumatoid arthritis (RA) who have inadequate response (IR) to TNF antagonists [abstract]. Arthritis Rheum 2008;58 Suppl:S617.